CAMBRIDGE, Mass., May 17, 2021 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC) today announced the
appointment of Percy Carter, MBA,
Ph.D., as Chief Scientific Officer, effective May 19, 2021. In this role, Dr. Carter will
oversee all of the company's research and preclinical
development.
"I am thrilled to welcome Percy to Blueprint Medicines. His
proven track record of advancing promising science into the clinic
and leading diverse, high-performing research teams will be
invaluable as we seek to further advance and expand our precision
therapy pipeline," said Fouad Namouni, M.D., President, Research
& Development at Blueprint Medicines. "With a passion for
impacting patients' lives through groundbreaking science, Percy
will continue to leverage the significant productivity of our
foundational research platform, and set our strategic vision for
extending into new areas of biology and treatment modalities. He
will play an instrumental role as we work to reproducibly discover
new precision medicines that address urgent patient needs, with a
focus in oncology and hematology."
"It is a great privilege to join Blueprint Medicines, a company
at the forefront of developing precision therapies with the
potential to fundamentally change patient outcomes," said Dr.
Carter. "What sets Blueprint Medicines apart is its ability to
design exquisitely selective and potent molecules against some of
the most challenging drug targets, and to rapidly translate
scientific advancements into innovative therapy options for
patients. I look forward to working with Blueprint Medicines'
talented scientists and applying the company's unique research
capabilities to help us define the future of precision therapy and
make real its promise for as many patients as
possible."
Dr. Carter brings more than 20 years of global leadership in
pharmaceutical companies and industry experience. Prior to joining
Blueprint Medicines, he served as Chief Scientific Officer at
FibroGen, Inc. He previously served as Global Head of Discovery
Sciences at Janssen Pharmaceuticals, Inc., a division of Johnson
& Johnson, where he led more than 700 employees comprising
several key research and discovery functions, and drove the
synthetic discovery strategy in collaboration with partners across
various therapeutic areas. From August
2001 to May 2019, Dr. Carter
held roles of increasing responsibility in drug discovery, covering
all therapeutic areas, drug platforms and stages of discovery at
Bristol-Myers Squibb (BMS), including serving as Senior Vice
President and Head of Discovery. Prior to his experience at BMS, he
was Senior Research Scientist in Chemical and Physical Sciences at
DuPont Pharmaceuticals, until it was acquired by BMS in 2001. Dr.
Carter is an inventor or co-inventor on more than 28 U.S. patents,
and has authored or co-authored numerous peer-reviewed
publications. Dr. Carter received an A.B. in Chemistry from
Dartmouth College and a Ph.D. in
Organic Chemistry from Harvard
University. In addition, he received an MBA from
Massachusetts Institute of
Technology.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing medicines for people with cancer and
hematologic disorders. Applying an approach that is both precise
and agile, we create therapies that selectively target genetic
drivers, with the goal of staying one step ahead across stages of
disease. Since 2011, we have leveraged our research platform,
including expertise in molecular targeting and world-class drug
design capabilities, to rapidly and reproducibly translate science
into a broad pipeline of precision therapies. Today, we are
delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple
programs for genomically defined cancers, systemic mastocytosis,
and cancer immunotherapy. For more information,
visit www.BlueprintMedicines.com and follow us
on Twitter (@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding expectations related to Blueprint Medicines' ability to
build an industry-leading portfolio of precision medicines;
expectations regarding Blueprint Medicines' ability to build on
core research and development activities and accelerate its
research pipeline; the potential benefits of Blueprint Medicines'
current and future approved drugs or drug candidates in treating
patients; and Blueprint Medicines' strategy, goals and anticipated
milestones, business plans and focus. The words "aim," "may,"
"will," "could," "would," "should," "expect," "plan," "anticipate,"
"intend," "believe," "estimate," "predict," "project," "potential,"
"continue," "target" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, risks and
uncertainties related to the impact of the COVID-19 pandemic to
Blueprint Medicines' business, operations, strategy, goals and
anticipated milestones, including Blueprint Medicines' ongoing and
planned research and discovery activities, ability to conduct
ongoing and planned clinical trials, clinical supply of current or
future drug candidates, commercial supply of current or future
approved products, and launching, marketing and selling current or
future approved products; Blueprint Medicines' ability and plans in
continuing to establish and expand a commercial infrastructure, and
successfully launching, marketing and selling current or future
approved products; Blueprint Medicines' ability to successfully
expand the approved indications for AYVAKIT™/AYVAKYT®
(avapritinib) and GAVRETO® (pralsetinib) or obtain
marketing approval for AYVAKIT/AYVAKYT in additional geographies in
the future; the delay of any current or planned clinical trials or
the development of Blueprint Medicines' current or future drug
candidates; Blueprint Medicines' advancement of multiple
early-stage efforts; Blueprint Medicines' ability to successfully
demonstrate the safety and efficacy of its drug candidates and gain
approval of its drug candidates on a timely basis, if at all; the
preclinical and clinical results for Blueprint Medicines' drug
candidates, which may not support further development of such drug
candidates; actions of regulatory agencies, which may affect the
initiation, timing and progress of clinical trials; Blueprint
Medicines' ability to obtain, maintain and enforce patent and other
intellectual property protection for AYVAKIT/AYVAKYT, GAVRETO or
any drug candidates it is developing; Blueprint Medicines' ability
to develop and commercialize companion diagnostic tests for
AYVAKIT/AYVAKYT, GAVRETO or any of its current and future drug
candidates; and the success of Blueprint Medicines' current and
future collaborations, partnerships or licensing arrangements.
These and other risks and uncertainties are described in greater
detail in the section entitled "Risk Factors" in Blueprint
Medicines' filings with the Securities and Exchange Commission
(SEC), including Blueprint Medicines' most recent Annual Report on
Form 10-K, as supplemented by its most recent Quarterly Report on
Form 10-Q and any other filings that Blueprint Medicines has made
or may make with the SEC in the future. Any forward-looking
statements contained in this press release represent Blueprint
Medicines' views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date.
Except as required by law, Blueprint Medicines explicitly disclaims
any obligation to update any forward-looking statements.
Trademarks
Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated
logos are trademarks of Blueprint Medicines Corporation.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-appoints-percy-carter-mba-phd-as-chief-scientific-officer-301291311.html
SOURCE Blueprint Medicines Corporation